skip to main content
Idioma:

Efficacy of the C-terminal telopeptide test in predicting the development of bisphosphonate-related osteonecrosis of the jaw: a systematic review

Dal Prá, K.J ; Lemos, C.A.A ; Okamoto, R ; Soubhia, A.M.P ; Pellizzer, E.P

International journal of oral and maxillofacial surgery, 2017-02, Vol.46 (2), p.151-156 [Periódico revisado por pares]

Denmark: Elsevier Ltd

Texto completo disponível

Citações Citado por
  • Título:
    Efficacy of the C-terminal telopeptide test in predicting the development of bisphosphonate-related osteonecrosis of the jaw: a systematic review
  • Autor: Dal Prá, K.J ; Lemos, C.A.A ; Okamoto, R ; Soubhia, A.M.P ; Pellizzer, E.P
  • Assuntos: Bisphosphonate-Associated Osteonecrosis of the Jaw - blood ; bisphosphonates ; C-terminal telopeptide ; Collagen Type I - blood ; CTX ; Dentistry ; Humans ; osteonecrosis ; Peptides - blood ; Predictive Value of Tests ; Risk Factors ; Surgery ; systematic review ; Tooth Extraction - adverse effects
  • É parte de: International journal of oral and maxillofacial surgery, 2017-02, Vol.46 (2), p.151-156
  • Notas: SourceType-Scholarly Journals-1
    ObjectType-Feature-4
    ObjectType-Undefined-1
    content type line 23
    ObjectType-Review-2
    ObjectType-Article-3
  • Descrição: Abstract This systematic review evaluated the efficacy of the morning fasting serum C-terminal telopeptide (CTX) test in predicting the development of bisphosphonate-related osteonecrosis of the jaw (BRONJ). A comprehensive search of studies published up to March 2016, and listed in the PubMed/MEDLINE, Web of Science, and Cochrane Library databases, was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. This review has been registered in the PROSPERO international prospective register of systematic reviews (CRD42016036717). The search identified 542 publications; eight studies were finally deemed eligible for inclusion according to the study criteria. These studies included a total 1442 patients (mean age 66.7 years). The most prescribed drug was alendronate, with osteoporosis being the most frequent indication for the prescription of bisphosphonates. Tooth extraction was the most common trigger for BRONJ. Of all patients evaluated after bisphosphonate treatment, only 24 (1.7%) developed BRONJ. All eight of the selected studies found that CTX levels were not predictive of the development of BRONJ. In conclusion, this systematic review indicates that the CTX test has no predictive value in determining the risk of osteonecrosis in patients taking bisphosphonates.
  • Editor: Denmark: Elsevier Ltd
  • Idioma: Inglês
Links
Voltar para lista de resultados
Ir para página anteriorAnterior Resultado  9 AvançarIr para próxima página

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.